Heart failure is a major public health concern because of its high prevalence (875 000 hospital admissions per year in the United States), poor prognosis (1-year mortality rate: 15 to 50%), high economic costs ($10 to $40 billion per year in the U.S.A.) and increasing incidence [1, 2] . Idiopathic dilated cardiomyopathy, a myocardial disease of unknown cause with left ventricular dilatation and impaired myocardial contractility [3, 4] , is a common cause of heart failure, is considered to cause nearly 50% of all dilated cardiomyopathies [5] and is also the primary indication for cardiac transplantation [6] . Although idiopathic dilated cardiomyopathy may be familial (in about 20% of cases) [7, 8] , most cases are sporadic and the disease is considered to be multifactorial, with genetic factors probably accounting for a significant part. We hypothesized that genetic abnormalities of the endothelin pathway may be involved in idiopathic dilated cardiomyopathy pathophysiology and therefore examined the possible association between idiopathic dilated cardiomyopathy and polymorphisms in genes encoding endothelin 1 and endothelin type A and type B receptors.
Methods

Study population
Patients with idiopathic dilated cardiomyopathy were enrolled in ten different hospitals in France. The CARDIGENE study was performed with hospital ethical committee approval. Diagnosis of idiopathic dilated cardiomyopathy was based on impaired left ventricular function (ejection fraction <40%) and left ventricular dilation (end-diastolic volume on ventriculography >140 ml . m 2 or end-diastolic diameter >34 mm . m 2 on echocardiography), confirmed over a 6-month period, in the absence of any cause of cardiac dilation [7] . Only patients of European origin, born in France and from parents born in France or neighbouring countries, were included. There were 433 patients with idiopathic dilated cardiomyopathy (mean age at diagnosis: 45 11 years, 345 men and 88 women, 229 patients had undergone a cardiac transplantation), the mean angiographic ejection fraction was 23 7%, the mean end-diastolic volume 195 67 ml . m 2 and the mean end-diastolic diameter on echocardiography was 40·1 5·1 mm . m 2 . The study control group consisted of 400 age-and sex-matched subjects free of cardiovascular disease selected from the population studies developed within the framework of the WHO/ MONICA (multinational monitoring of trends and determinants of cardiovascular diseases) project in France [9] .
Genetic polymorphisms
We investigated the role of bi-allelic polymorphisms in three main genes of the endothelin system: endothelin 1, and endothelin type A and B receptor genes. Since very few genetic polymorphisms have been described in these genes, systematic screening was first performed to identify them extensively [10] (description available at URL: http://ifr69.vjf.inserm.fr/canvas/). We investigated the Exon 1 (+138 A insertion) and Exon 5 (+61 G/T) polymorphisms in the endothelin 1 gene; the 231 A/G and Exon 8 (+1363 C/T) polymorphisms in the endothelin type A gene; and the Exon 4 (+30 A/G) in the endothelin type B gene (the numbering of the polymorphisms located in exons is relative to the first nucleotide of the exon). The two polymorphisms in the endothelin 1 gene, and those in the endothelin type A gene, were in weak linkage disequilibrium (respectively, D = 0·32 and D = +0·14, P<0·05 for both).
DNA extraction and polymorphisms genotyping
For each polymorphism, the genotype of cases and controls was determined after polymerase chain reaction amplification and allele-specific oligonucleotide hybridization. Genomic DNA was prepared from white blood cells by phenol extraction. The DNA fragment containing the Exon 8 C/T polymorphism in the endothelin type A gene was amplified by polymerase chain reaction using the following primers: U, 5 GAAGTCTAAAAC ACACCTAA3 and L, 5 CCCTTTGAAATGGTGAC AAT3 . polymerase chain reaction was performed with 100 ng of genomic DNA, 40 pmoles of each primer, and 1·25 U of Taq polymerase in a final volume of 50 l. Amplification conditions were 94 C for 5 min, followed by 30 cycles of 94 C for 1 min, 56 C for 1 min, and 72 C for 1 min followed by 72 C for 10 min. Specific allele-specific oligonucleotide probes for the Exon 8 C/T polymorphism were W: 5 CTTCACTTCTTGGGGTT3 (Tm 50 C) and M: 5 CTTCACTTTTTGGGGTT3 (Tm 48 C). Other polymorphisms were amplified according to experimental methods described at URL: http://ifr69.vjf.inserm.fr/canvas/. Each polymerase chain reaction product was denatured (NaOH 0·5 M, NaCl 1·5 M), then spotted on nylon membranes (Hybond+, Amersham, France), neutralized with SSC 2X, and cross-linked with ultraviolet light. Each membrane was then successively hybridized with specific oligonucleotide probes corresponding to genetic variants, at the melting temperature of the probe (Tm) 5 C, and then washed at Tm 2 C. Probes were labelled either with 32 P, or by a non radioactive method using labelling with fluorescein (ECL, Amersham, France) and detection by chemiluminescence (Amersham, France).
Statistical analyses
The Hardy-Weinberg equilibrium was tested by chisquare test with 1 df. Differences in the distribution of genotype or allele frequencies between cases and control subjects were compared by chi-square analysis. Data were analysed with SAS statistical software (SAS Institute Inc.) and a P value <0·05 was considered statistically significant.
Results
Distributions of genotypes for each polymorphism in cases and in control subjects are shown in Table 1 . Allele frequencies in the control and patient groups were consistent with the Hardy-Weinberg equilibrium for all polymorphisms. No significant difference was observed in genotype or allele frequencies between cases and controls, except for the +1363 Cytosine/Thymine polymorphism in the non translated part of Exon 8 of the endothelin type A gene (abbreviated Exon 8 C/T) ( Table 1) .
Analysis of the Exon 8 C/T polymorphism in the endothelin type A gene (Table 1) indicated that the distribution of genotype frequencies was significantly different in cases and in control subjects (P=0·02), as was the distribution of allele frequencies (P=0·045). The association of the T allele with the disease was mainly due to an increased frequency of the T/T homozygotes among patients, suggesting a recessive mode of action of endothelin type A receptor gene polymorphism on idiopathic dilated cardiomyopathy. The odds ratio for the disease associated with the T/T genotype was 1·9 (95% confidence interval: 1·2 to 3·01; P<0·006).
Analysis of subgroups (cut-offs for continuous variables were determined by median values) indicated that the association between the T/T genotype of Exon 8 polymorphism (in the endothelin type A gene) and the disease was strengthened in the youngest subjects (<45 years; n=413; OR: 2·39; 95% CI: 1·25 to 4·58, P<0·009), where genetic factors are expected to be important, while being weaker in older subjects (>45 years; n=413; OR: 1·5; 95% CI: 0·79 to 2·88, test for interaction: P=0·33). Finally and within the patient group, there were no relationships between genotype and the severity of the disease, assessed by ejection fraction, left ventricular dilation, or cardiac transplantations ( Table 2 ).
Discussion
In this study, analysis of Exon 8 C/T polymorphism in the endothelin type A gene indicated that individuals who are homozygote for the T allele were at significantly increased risk for idiopathic dilated cardiomyopathy. Our results are strengthened by methodological cautions. First, the CARDIGENE study included more than 400 patients with idiopathic dilated cardiomyopathy, which is the largest analysed population to date, providing an important statistical power, reasonably appropriate to detect a meaningful genetic risk factor. Second, subjects were selected to minimize population heterogeneity (see Methods), and to minimize clinical heterogeneity since robust diagnostic criteria were used. The allele frequencies in the control group were, in addition, similar to those previously described in the French population of the ECTIM study (Etude Cas-Témoins sur l'Infarctus du Myocarde) [10] . Several lines of evidence support the involvement of the endothelin system in the pathophysiology of heart failure. Physiological effects of isoform 1 of endothelin on the cardiovascular system include vasoconstriction, positive inotropic and chronotropic effects on the myocardium, and growth-promoting effects contributing to the development of myocardial hypertrophy (review in [11, 12] ). These cardiovascular effects are mediated mainly by endothelin type A receptors. In heart failure, plasma LVED=left ventricular end diastolic (diameter on echocardiography or volume on ventriculography). Mean SD is indicated for continuous variables. For all parameters, differences between genotypes were not significant.
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endothelin 1 concentration is increased, and there is also an up-regulation of the myocardial endothelin pathway with increased endothelin 1 and endothelin mRNA receptors, and increased endothelin receptor density [13, 14] . Pharmacological studies with endothelin receptor antagonists in experimental models of heart failure suggest that the endothelin pathway exerts beneficial effects during the early stage of heart failure because acute application of endothelin antagonists decreases myocardial contractility [13] . However, prolonged stimulation may have important maladaptative effects on myocardial structure and function since long-term treatment with endothelin antagonists in rats with heart failure improved survival rates and haemodynamics, and prevented left ventricular dilation [15, 16] . The functional consequences of Exon 8 C/T polymorphism (located after the stop codon) in the endothelin type A gene are unknown since functional studies are not yet available. This polymorphism in the 3 -untranslated region might be related to regulatory sequences of the transcription of the gene and thus be associated with differences in the level of gene expression, as described for other genes such as the prothrombin gene [17] . Moreover, Exon 8 C/T polymorphism in the endothelin type A gene was recently associated with pulse pressure in humans [10] . In idiopathic dilated cardiomyopathy, several hypotheses can be suggested, based on the assumption that the polymorphism modulates the expression level or the function of the endothelin type A receptor: (1) a loss of expression/ function may be deleterious during the early stage of heart failure, where the endothelin system may play a role in the maintenance of cardiac function; (2) conversely, a gain of expression/function might be beneficial in the early stage but could promote accelerated myocardial remodelling and dysfunction in more advanced stages of the disease. Finally, we cannot exclude the possibility that another genetic variant, in linkage disequilibrium with Exon 8 polymorphism, causes the observed association.
In previous studies, available genetic data about non familial forms of idiopathic dilated cardiomyopathy is very limited. Insertion/deletion polymorphism in the angiotensin converting enzyme was investigated and results are controversial. One study reported an association between insertion/deletion ACE polymorphism and idiopathic dilated cardiomyopathy [18] but this result was questioned because of methodological bias [19] . Furthermore, subsequent well-designed studies failed to find any association between this polymorphism and the disease [19] [20] [21] . Other candidate genes were also examined in idiopathic dilated cardiomyopathy. In Japanese patients, a polymorphism in the PAF acethyl hydrolase gene was associated with the disease [22] . No association was found with a polymorphism in the TNF-alpha gene [23] . We recently characterized a unique polymorphism in the beta1-adrenoreceptor gene and found no association with idiopathic dilated cardiomyopathy [24] .
In conclusion, we found that a variant of the endothelin type A receptor gene is a possible and potent genetic risk factor for idiopathic dilated cardiomyopathy. Since genetic data in previous studies is very limited and controversial, this variant in the endothelin type A receptor gene can be considered as one of the first identified genetic risk factors for idiopathic forms of heart failure, and the first in a European population. This result has to be confirmed by other independant studies, since genetic association studies should be carefully considered, and the functional significance of the variant remains to be elucidated. However, our results provide a new approach to the pathophysiology of the disease, and they also could lead to a better identification of individuals at risk. This finding strengthens the interest of clinical studies with endothelin receptor antagonists and might help in defining subgroups of responders to such treatment.
